Kangmei Pharmaceutical Co., Ltd. (SHA: 600518)
China
· Delayed Price · Currency is CNY 2.060
+0.170 (8.99%)
Sep 30, 2024, 3:00 PM CST
Kangmei Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 4,932 | 4,827 | 4,161 | 4,054 | 5,267 | 11,329 | Upgrade
|
| Other Revenue | 39.44 | 47.3 | 18.95 | 98.79 | 144.52 | 116.18 | Upgrade
|
| Revenue | 4,971 | 4,874 | 4,180 | 4,153 | 5,412 | 11,446 | Upgrade
|
| Revenue Growth (YoY) | 4.04% | 16.60% | 0.67% | -23.27% | -52.72% | -32.93% | Upgrade
|
| Cost of Revenue | 4,315 | 4,159 | 3,749 | 4,061 | 29,046 | 10,498 | Upgrade
|
| Gross Profit | 655.95 | 715.07 | 431.14 | 91.52 | -23,634 | 948.02 | Upgrade
|
| Selling, General & Admin | 885.76 | 1,015 | 1,037 | 1,283 | 2,021 | 2,289 | Upgrade
|
| Research & Development | 44.83 | 45.62 | 25.45 | 9.27 | 11.36 | 110.06 | Upgrade
|
| Other Operating Expenses | -329.39 | -312.48 | 195.22 | 653.49 | 122.99 | 218.78 | Upgrade
|
| Operating Expenses | 345.46 | 509.72 | 1,471 | 3,138 | 3,158 | 2,652 | Upgrade
|
| Operating Income | 310.49 | 205.36 | -1,040 | -3,046 | -26,793 | -1,704 | Upgrade
|
| Interest Expense | -55.99 | -56.15 | -78.9 | -1,022 | -2,164 | -2,249 | Upgrade
|
| Interest & Investment Income | 86.62 | 75.18 | 40.77 | 194.06 | 2.17 | 772.94 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -0.02 | -0.27 | 25.44 | Upgrade
|
| Other Non Operating Income (Expenses) | -25.73 | -38.02 | -16.04 | -1,041 | -137.84 | -209.21 | Upgrade
|
| EBT Excluding Unusual Items | 315.4 | 186.36 | -1,095 | -4,915 | -29,093 | -3,364 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -44.29 | -111.21 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.03 | -0.03 | - | - | -4.59 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 27.6 | 19.61 | 0.98 | 64.01 | -45.24 | -19.03 | Upgrade
|
| Asset Writedown | -98.97 | -99.69 | -307.46 | -2,634 | -1,424 | -476.61 | Upgrade
|
| Legal Settlements | -37.19 | -37.19 | -331.49 | -1,576 | -516.22 | -500 | Upgrade
|
| Other Unusual Items | 43.84 | 41.31 | -931.58 | 17,217 | 93.85 | 79.57 | Upgrade
|
| Pretax Income | 250.65 | 110.37 | -2,664 | 8,155 | -31,033 | -4,391 | Upgrade
|
| Income Tax Expense | 3.9 | 6.8 | 29.75 | 235.39 | 62.55 | 264.13 | Upgrade
|
| Earnings From Continuing Operations | 246.75 | 103.57 | -2,694 | 7,920 | -31,096 | -4,655 | Upgrade
|
| Minority Interest in Earnings | -2.61 | -1.05 | 5.64 | -2 | 11.19 | -5.47 | Upgrade
|
| Net Income | 244.14 | 102.52 | -2,688 | 7,918 | -31,085 | -4,661 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 225 | Upgrade
|
| Net Income to Common | 244.14 | 102.52 | -2,688 | 7,918 | -31,085 | -4,886 | Upgrade
|
| Shares Outstanding (Basic) | 11,140 | 10,252 | 14,148 | 13,891 | 13,815 | 4,937 | Upgrade
|
| Shares Outstanding (Diluted) | 11,140 | 10,252 | 14,148 | 13,891 | 13,815 | 4,937 | Upgrade
|
| Shares Change (YoY) | -21.29% | -27.54% | 1.85% | 0.55% | 179.83% | -20.41% | Upgrade
|
| EPS (Basic) | 0.02 | 0.01 | -0.19 | 0.57 | -2.25 | -0.99 | Upgrade
|
| EPS (Diluted) | 0.02 | 0.01 | -0.19 | 0.57 | -2.25 | -0.99 | Upgrade
|
| Free Cash Flow | -533.66 | -417.27 | -798.08 | 42.58 | 729.67 | 2,409 | Upgrade
|
| Free Cash Flow Per Share | -0.05 | -0.04 | -0.06 | 0.00 | 0.05 | 0.49 | Upgrade
|
| Gross Margin | 13.19% | 14.67% | 10.31% | 2.20% | - | 8.28% | Upgrade
|
| Operating Margin | 6.25% | 4.21% | -24.89% | -73.37% | -495.06% | -14.89% | Upgrade
|
| Profit Margin | 4.91% | 2.10% | -64.31% | 190.68% | -574.37% | -42.69% | Upgrade
|
| Free Cash Flow Margin | -10.73% | -8.56% | -19.09% | 1.03% | 13.48% | 21.05% | Upgrade
|
| EBITDA | 590.24 | 490.98 | -730.42 | -2,493 | -26,148 | -1,009 | Upgrade
|
| EBITDA Margin | 11.87% | 10.07% | -17.47% | -60.04% | - | -8.82% | Upgrade
|
| D&A For EBITDA | 279.75 | 285.62 | 309.93 | 553.19 | 644.83 | 695.14 | Upgrade
|
| EBIT | 310.49 | 205.36 | -1,040 | -3,046 | -26,793 | -1,704 | Upgrade
|
| EBIT Margin | 6.25% | 4.21% | -24.89% | -73.36% | - | -14.89% | Upgrade
|
| Effective Tax Rate | 1.56% | 6.16% | - | 2.89% | - | - | Upgrade
|
| Revenue as Reported | 4,971 | 4,874 | 4,180 | 4,153 | 5,412 | 11,446 | Upgrade
|
| Advertising Expenses | - | 192.3 | 114.06 | 99.5 | 259.46 | 546.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.